|
|
News Breaks | | | | June 30, 2012 | | 10:54 EDT |  | AMAG, TKPYY | AMAG and Takeda amend existing license agreement
AMAG Pharmaceuticals (AMAG), and Takeda Pharmaceutical (TKPYY) entered into an Amendment to License, Development and Commercialization Agreement, or the Takeda Amendment, which amended and restated the existing License, Development and Commercialization Agreement and which amendment was deemed effective as of June 22. The License, Development and Commercialization Agreement with Takeda, dated March 31, 2010, was amended by the Takeda Amendment to, among other things, modify the territories under which Takeda has exclusive rights to develop and commercialize FerahemeŽ (ferumoxytol) Injection for Intravenous use as a therapeutic agent, amend the timing and pricing arrangements for a Supply Agreement to be entered into between the Company and Takeda in the future, amend the terms related to primary and secondary manufacturing sources for drug substance and drug product of ferumoxytol, amend certain patent related provisions, and change the allocation of certain of the agreed upon milestone payments. | |
|
News For AMAG;TKPYY From The Last 14 Days Check below for free stories on AMAG;TKPYY the last two weeks. |
|
|
| May 21, 2013 | | 18:56 EDT | | AMAG, TKPYY | On The Fly: After Hours Movers
 Subscribe for More Information | | | 17:34 EDT | | AMAG, TKPYY | AMAG says Takeda recalling one batch of Rienso from Swiss market
Subscribe for More Information | | | 08:47 EDT | | AMAG | AMAG Pharmaceuticals Ferumoxytol treatment significant hemoglobin increases
AMAG Pharmaceuticals announced that a new sub-group analysis from IDA-301, a phase III, randomized, placebo-controlled clinical trial, will be presented today at the Digestive Disease Week 2013 meeting in Orlando, Florida. In the full IDA-301 study, 608 adult patients with iron deficiency anemia who had failed or could not tolerate oral iron were treated with ferumoxytol and 200 received placebo. The data from this study showed a direct correlation between a rise in hemoglobin levels and improvements in patients' self-reported measures of fatigue. GI patients with iron deficiency anemia who have not responded well to oral iron supplementation have a need for additional treatment options. The analysis from this study supports the potential of ferumoxytol as a new treatment option for patients with IDA from GI disease who have previously had an unsatisfactory response to oral iron therapy | | | May 15, 2013 | | 09:53 EDT |  | AMAG | AMAG Pharmaceuticals management to meet with Leerink
Subscribe for More Information | | | May 7, 2013 | | 19:03 EDT | | TKPYY | Takeda to buy Inviragen
Subscribe for More Information | | | 17:57 EDT | | TKPYY | Sucampo expects to recognize $10M milestone payment for Amitiza in Q2
The payment is from Takeda Pharmaceutical (TKPYY). | |
|
|
|
|
|
|
